Financials Sinopharm Group Co. Ltd.

Equities

Delayed Hong Kong S.E. Other stock markets 01:59:21 2025-07-09 am EDT			5-day change	1st Jan Change
18.48 ^HKD	+0.22%		-0.22%	-13.33%

Jun. 12	Sinopharm Group Co. Ltd. Approves Board Appointments	CI
Jun. 10	Sinopharm Unit to Acquire 21% Stake in Pacific Shuanglin Bio-pharmacy	MT

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	456,415	521,051	552,148	596,570	584,508	597,882	627,378	656,680
Change	-	14.16%	5.97%	8.05%	-2.02%	2.29%	4.93%	4.67%
EBITDA ¹	19,667	23,634	24,769	24,639	24,680	20,977	22,227	23,186
Change	-	20.17%	4.8%	-0.53%	0.16%	-15%	5.96%	4.31%
EBIT ¹	17,760	19,712	20,604	20,209	22,362	17,747	18,505	19,513
Change	-	10.99%	4.53%	-1.92%	10.65%	-20.64%	4.27%	5.45%
Interest Paid ¹	-2,947	-3,403	-3,509	-2,430	-2,328	-2,448	-2,236	-2,382
Earnings before Tax (EBT) ¹	15,598	17,003	18,564	19,512	14,001	15,410	16,302	17,191
Change	-	9.01%	9.18%	5.11%	-28.25%	10.07%	5.78%	5.45%
Net income ¹	7,187	7,759	8,526	9,054	7,050	7,632	8,350	8,675
Change	-	7.95%	9.89%	6.19%	-22.14%	8.26%	9.41%	3.89%
Announcement Date	3/21/21	3/20/22	3/26/23	3/24/24	3/23/25	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1
Net sales ¹	18,687	155,433	144,969	150,650	147,266	147,461	147,696	142,085	141,662
Change	-	731.78%	-6.73%	3.92%	-2.25%	0.13%	0.16%	-3.8%	-0.3%
EBITDA	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EBIT	-	5,895	5,937	4,691	-	-	5,229	-	-
Change	-	-	0.71%	-20.99%	-	-	-	-	-
Charge d'intérêts	-	-	-	-934.3	-	-	-56.75	-	-
Earnings before Tax (EBT)	-	5,228	4,161	6,485	-	4,463	3,239	3,166	-
Change	-	-	-20.42%	55.87%	-	-	-27.42%	-2.26%	-
Net income	362.2	2,514	1,752	-	1,420	-	1,575	-	-
Change	-	594.11%	-30.29%	-	-	-	-	-	-
Announcement Date	4/17/23	8/27/23	10/30/23	3/24/24	4/29/24	8/26/24	10/28/24	3/23/25	4/28/25

¹CNY in Million

Estimates

Fiscal Period: December	2020 S2	2021 S1	2021 S2	2022 S1	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2	2025 S1	2025 S2	2026 S1	2026 S2
Net sales ¹	252,650	249,120	271,931	261,472	290,676	300,950	295,619	294,727	289,781	290,437	295,783	297,156	299,144
Change	-	-1.4%	9.16%	-3.85%	11.17%	3.53%	-1.77%	-0.3%	-1.68%	0.23%	1.84%	0.46%	0.67%
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-	8,772	10,940	9,057	11,547	10,869	10,628	9,549	12,813	8,046	10,240	8,138	10,255
Change	-	-	24.71%	-17.21%	27.5%	-5.87%	-2.22%	-10.15%	34.18%	-37.2%	27.26%	-20.52%	26.01%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-	8,866	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income	-	-	-	-	-	4,104	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	3/21/21	8/22/21	3/20/22	8/29/22	3/26/23	8/27/23	3/24/24	8/26/24	3/23/25	-	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	13,699	20,041	9,526	13,343	17,053	-4,855	-9,210	-23,654
Change	-	46.3%	-52.47%	40.07%	27.8%	-128.47%	-89.7%	-156.83%
Announcement Date	3/21/21	3/20/22	3/26/23	3/24/24	3/23/25	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	4,585	2,807	2,482	2,488	2,461	2,272	2,474	2,496
Change	-	-38.78%	-11.57%	0.24%	-1.1%	-7.67%	8.88%	0.89%
Free Cash Flow (FCF) ¹	-4,574	6,501	18,481	14,685	9,085	24,063	13,270	15,349
Change	-	242.12%	184.29%	-20.54%	-38.13%	164.86%	-44.86%	15.67%
Announcement Date	3/21/21	3/20/22	3/26/23	3/24/24	3/23/25	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	4.31%	4.54%	4.49%	4.13%	4.22%	3.51%	3.54%	3.53%
EBIT Margin (%)	3.89%	3.78%	3.73%	3.39%	3.83%	2.97%	2.95%	2.97%
EBT Margin (%)	3.42%	3.26%	3.36%	3.27%	2.4%	2.58%	2.6%	2.62%
Net margin (%)	1.57%	1.49%	1.54%	1.52%	1.21%	1.28%	1.33%	1.32%
FCF margin (%)	-1%	1.25%	3.35%	2.46%	1.55%	4.02%	2.12%	2.34%
FCF / Net Income (%)	-63.64%	83.79%	216.77%	162.19%	128.87%	315.28%	158.91%	176.94%
Profitability
ROA	2.47%	2.4%	2.44%	2.42%	1.82%	1.86%	2.17%	2.22%
ROE	13.85%	13.12%	13.12%	12.69%	9.19%	9.11%	9.34%	9.42%
Financial Health
Leverage (Debt/EBITDA)	0.7x	0.85x	0.38x	0.54x	0.69x	-	-	-
Debt / Free cash flow	-3x	3.08x	0.52x	0.91x	1.88x	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	1%	0.54%	0.45%	0.42%	0.42%	0.38%	0.39%	0.38%
CAPEX / EBITDA (%)	23.31%	11.88%	10.02%	10.1%	9.97%	10.83%	11.13%	10.76%
CAPEX / FCF (%)	-100.24%	43.18%	13.43%	16.95%	27.09%	9.44%	18.64%	16.26%
Items per share
Cash flow per share ¹	3.585	2.983	6.718	5.503	3.704	8.752	3.783	4.687
Change	-	-16.81%	125.23%	-18.08%	-32.68%	136.25%	-56.78%	23.91%
Dividend per Share ¹	0.69	0.75	0.82	0.87	0.68	0.7487	0.7991	0.8479
Change	-	8.7%	9.33%	6.1%	-21.84%	10.1%	6.73%	6.1%
Book Value Per Share ¹	18.12	19.83	21.81	23.9	25.28	27.17	29.92	32.36
Change	-	9.47%	9.99%	9.57%	5.77%	7.48%	10.13%	8.14%
EPS ¹	2.31	2.49	2.73	2.9	2.26	2.474	2.693	2.818
Change	-	7.79%	9.64%	6.23%	-22.07%	9.47%	8.85%	4.64%
Nbr of stocks (in thousands)	3,120,656	3,120,656	3,120,656	3,120,656	3,120,656	3,120,656	3,120,656	3,120,656
Announcement Date	3/21/21	3/20/22	3/26/23	3/24/24	3/23/25	-	-	-